Thus, given that K-ras 4A and 4B are co-expressed widely in mammalian tissues [12,18] it remains to be determined whether their ratio is altered in other types of tumours that routinely lack K-ras activating mutations. The gene discussed is KRAS; the disease is neoplasm.